Abstract

Background: Is it well-known that one of the major drawbacks of Lupus Anticoagulant (LA) test is their sensitivity to anticoagulant therapy, due to the coagulation based principle. In this study we aimed to assess the reproducibility of LA testing and to evaluate the performance of solid assay phosphatidylserine/prothrombin (aPS/PT) antibodies.Methods: We included 60 patients that fulfilled the following inclusion criteria: (I) diagnosis of thrombotic antiphospholipid syndrome (APS); (II) patients with thrombosis and (a) inconstant previous LA positivity and/or (b) positivity for antiphospholipid antibodies (aPL) at low-medium titers [defined as levels of anti-β2Glycoprotein-I or anticardiolipin (IgG/IgM) 10–30 GPL/MPL] with no previous evidence of LA positivity. aPL testing was performed blindly in 4 centers undertaking periodic external quality assessment.Results: The 60 patients enrolled were distributed as follows: 43 (71.7%) with thrombotic APS, 7 (11.7%) with thrombosis and inconstant LA positivity and 10 (16.7%) with low-medium aPL titers. Categorical agreement for LA among the centers ranged from 0.41 to 0.60 (Cohen's kappa coefficient; moderate agreement). The correlation determined at the 4 sites for aPS/PT was strong, both quantitatively (Spearman rho 0.84) and when dichotomized (Cohen's kappa coefficients = 0.81 to 1.0). Discordant (as defined by lack of agreement in ≥3 laboratories) or inconclusive LA results were observed in 27/60 (45%) cases; when limiting the analysis to those receiving vitamin K antagonist (VKA), the level of discordant LA results was as high as 75%(15/20). Conversely, aPS/PT testing showed an overall agreement of 83% (up to 90% in patients receiving VKA), providing an overall increase in test reproducibility of +28% when compared to LA, becoming even more evident (+65%) when analyzing patients on VKA. In patients treated with VKA, we observed a good correlation for aPS/PT IgG testing (Cohen's kappa coefficients = 0.81–1; Spearman rho 0.86).Conclusion: Despite the progress in the standardization of aPL testing, we observed up to 45% of overall discrepant results for LA, even higher in patients on VKA. The introduction of aPS/PT testing might represent a further diagnostic tool, especially when LA testing is not available or the results are uncertain.

Highlights

  • Since clinical features of Antiphospholipid Syndrome (APS) are common in the general population and often related to other underlying factors, the diagnosis of APS requires next to clinical assessment the detection of persistently positive Antiphospholipid Antibodies

  • Forty-three patients (71.7%) had a confirmed diagnosis of thrombotic APS, and 17 patients presented with thrombosis and inconsistent Lupus anticoagulant (LA) positivity [7/17 (41.2%)] and/or with lowmedium titers [10/17(58.8%)]

  • We observed 27 (45.0% of the total) cases (15/20, 75% patients on vitamin K antagonists (VKA)) in which LA results were discordant or inconclusive. In those cases, we observed a good correlation for assay phosphatidylserine/prothrombin (aPS/PT) IgG/IgM testing (Cohen’s kappa coefficients = 0.81–1.00, Spearman rho 0.86)

Read more

Summary

Introduction

Since clinical features of Antiphospholipid Syndrome (APS) (thrombosis and pregnancy complications) are common in the general population and often related to other underlying factors, the diagnosis of APS requires next to clinical assessment the detection of persistently positive Antiphospholipid Antibodies (aPL). Lupus anticoagulant (LA) has been shown to be the strongest risk factor for aPL-related clinical manifestations [4], and the correct interpretation of this functional assay is crucial for diagnosis of APS. The clinical significance of low aPL titer and/or weak LA positivity, especially when detected in patients receiving anticoagulation [either VKA or direct anticoagulant agents (DOAC)], remains uncertain and certainly needs a more thorough evaluation. Is it well-known that one of the major drawbacks of Lupus Anticoagulant (LA) test is their sensitivity to anticoagulant therapy, due to the coagulation based principle. In this study we aimed to assess the reproducibility of LA testing and to evaluate the performance of solid assay phosphatidylserine/prothrombin (aPS/PT) antibodies

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call